MYT1L mutations cause intellectual disability and variable obesity by dysregulating gene expression and development of the neuroendocrine hypothalamus

• Published in: PLoS genetics Vol. 13; no. 8; p. e1006957
• Main Authors: Blanchet, Patricia, Bebin, Martina, Bruet, Shaam, Cooper, Gregory M, Thompson, Michelle L, Duban-Bedu, Benedicte, Gerard, Benedicte, Piton, Amelie, Suckno, Sylvie, Deshpande, Charu, Clowes, Virginia, Vogt, Julie, Turnpenny, Peter, Williamson, Michael P, Alembik, Yves, Glasgow, Eric, McNeill, Alisdair
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 01.08.2017; Public Library of Science (PLoS)
• Subjects: Adult; Animals; Autism; Bioinformatics; Biology and Life Sciences; Biotechnology; Brain research; Cell Line; Child; Chromosome 19; Chromosome Deletion; Chromosomes, Human, Pair 2 - genetics; Clonal deletion; Congenital diseases; Consortia; CRISPR; CRISPR-Cas Systems; Female; Funding; Gene deletion; Gene expression; Gene Expression Regulation - genetics; Gene Knockout Techniques; Genetics; Genomes; Genomics; Hospitals; Humans; Hypothalamus; Hypothalamus - metabolism; Hypothalamus - pathology; Hypothalamus - physiology; Intellectual disabilities; Intellectual Disability - genetics; Intellectual Disability - physiopathology; Male; Medicine and Health Sciences; Mutation; Nerve Tissue Proteins - genetics; Obesity; Obesity - genetics; Obesity - physiopathology; Ontology; Oxytocin; Polymorphism, Single Nucleotide - genetics; Research and Analysis Methods; Rodents; Social Sciences; Transcription Factors - genetics; Zebrafish; Alabama; United States > US
• ISSN: 1553-7404; 1553-7390; 1553-7404
• DOI: 10.1371/journal.pgen.1006957

Deletions at chromosome 2p25.3 are associated with a syndrome consisting of intellectual disability and obesity. The smallest region of overlap for deletions at 2p25.3 contains PXDN and MYT1L. MYT1L is expressed only within the brain in humans. We hypothesized that single nucleotide variants (SNVs) in MYT1L would cause a phenotype resembling deletion at 2p25.3. To examine this we sought MYT1L SNVs in exome sequencing data from 4, 296 parent-child trios. Further variants were identified through a genematcher-facilitated collaboration. We report 9 patients with MYT1L SNVs (4 loss of function and 5 missense). The phenotype of SNV carriers overlapped with that of 2p25.3 deletion carriers. To identify the transcriptomic consequences of MYT1L loss of function we used CRISPR-Cas9 to create a knockout cell line. Gene Ontology analysis in knockout cells demonstrated altered expression of genes that regulate gene expression and that are localized to the nucleus. These differentially expressed genes were enriched for OMIM disease ontology terms "mental retardation". To study the developmental effects of MYT1L loss of function we created a zebrafish knockdown using morpholinos. Knockdown zebrafish manifested loss of oxytocin expression in the preoptic neuroendocrine area. This study demonstrates that MYT1L variants are associated with syndromic obesity in humans. The mechanism is related to dysregulated expression of neurodevelopmental genes and altered development of the neuroendocrine hypothalamus.